Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Waters Shares Surge on Bullish Analyst Initiation

Robert Sasse by Robert Sasse
October 9, 2025
in Analysis, Industrial, Pharma & Biotech
0
Waters Stock
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

Waters Corporation witnessed a significant uptick in its stock price yesterday, climbing 3.3% to close at $328.73. This notable advance was primarily fueled by Rothschild Redburn, which commenced coverage of the company with a highly optimistic “Buy” recommendation. The financial services firm set a price target of $390 for the shares, indicating substantial potential upside from current levels.

Strong Fundamentals Underpin Positive Outlook

The company’s robust financial health provides a solid foundation for this bullish sentiment. For the second quarter of 2025, Waters reported revenue of $771 million, exceeding market expectations and delivering an 8% increase in earnings. The firm’s gross margin stood at an impressive 59.02%, highlighting its operational efficiency and pricing power within the sector.

Rothschild Redburn’s analysis emphasized Waters’ position as the premier pure-play provider in analytical instruments, noting its industry-leading EBITA margins of 31%. A key strength identified was the company’s recurring revenue model, with approximately 60% of sales originating from services and consumables dedicated to the pharmaceutical industry.

Strategic Acquisition Reshapes Market Position

A transformative development for Waters is its planned acquisition of Becton Dickinson’s biosciences and diagnostics division, valued at $17.5 billion. Market experts view this transaction as a potential game-changer that will effectively double the company’s addressable market to an estimated $40 billion. This expanded market is projected to grow at an annual rate of 5-7%, providing significant long-term growth opportunities.

Should investors sell immediately? Or is it worth buying Waters?

The acquisition process is expected to conclude in early 2026, positioning the combined entity as a dominant force in the life sciences sector. According to Rothschild Redburn’s projections, the merged company could achieve annual EPS growth of 14% through 2029.

Divergent Views Create Market Uncertainty

While Rothschild Redburn expresses strong conviction, the broader analyst community presents a more varied perspective. Weiss Ratings simultaneously reaffirmed its “Hold” rating on Waters shares. Other financial institutions, including Stifel and KeyBanc, maintain positions ranging from “Hold” to “Overweight,” reflecting differing assessments of how the acquisition will impact the company’s future performance.

Market participants are looking toward November 4th for greater clarity, when Waters is scheduled to release its quarterly earnings. This upcoming report could determine whether the stock maintains its upward trajectory or faces a corrective phase, making the current trading environment particularly significant for investors monitoring this evolving situation.

Ad

Waters Stock: Buy or Sell?! New Waters Analysis from February 7 delivers the answer:

The latest Waters figures speak for themselves: Urgent action needed for Waters investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Waters: Buy or sell? Read more here...

Tags: Waters
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

ServiceNow Stock
AI & Quantum Computing

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Next Post
Thermo Fisher Scientific Stock

Thermo Fisher's Diagnostic Breakthrough Could Reverse Stock Fortunes

Mastercard Stock

Mastercard Doubles Down on Digital Growth and AI Security

Beyond Meat Stock

Plant-Based Pioneer Faces Regulatory and Financial Crossroads

Recommended

Eli Lilly Stock

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

3 months ago
Applovin Stock

Regulatory Storm Clouds Gather Over Applovin

4 months ago
Apple Stock

Berkshire’s Apple Share Sale Sparks Market Speculation Ahead of Key Launch

5 months ago
Asml Stock

Is ASML Stock Presenting a Major Buying Opportunity?

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Trending

ServiceNow Stock
AI & Quantum Computing

ServiceNow Shares Face Market Skepticism Despite Record Performance

by Jackson Burston
February 7, 2026
0

In late January 2026, ServiceNow reported quarterly financial results that surpassed even the most optimistic projections from...

Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • ServiceNow Shares Face Market Skepticism Despite Record Performance
  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com